Table 2.

Adverse events reported by participants.

Adverse Event	Exenatide (N=13)	Placebo (N=14)	P-value (2s)
Nausea	5 (38%)	0	0.016
GERD symptoms	2 (15%)	1 (7%)	0.596
Upper GI upset (nausea + GERD + non-specific complaints)	8 (62%)	1 (7%)	0.004
Loss of appetite/weight loss	4 (31%)	0	0.041
Changes in taste (dysgeusia)	0	1 (7%)	1.000
Lower GI upset (Diarrhea)	3 (23%)	1 (7%)	0.326
Transient abdominal pain (non-specific)	1 (8%)	0	0.481
Transient asymptomatic elevation in pancreatic enzymes (amylase, lipase)	2 (15%)	2 (14%)	0.673
Dizziness/lightheadedness/diaphoresis (symptoms suspicious for hypoglycemia)	3 (23%)	2 (14%)	0.648
Injection site ecchymosis/pain	1 (8%)	1 (7%)	1.000
Abnormal kidney function tests (BUN, Creatine)	2 (15%)	2 (14%)	1.000
Other (fatigue, allergic conjuctivitis, etc.)	3 (23%)	1 (7%)	0.326

Adverse events incidence and percentage in the placebo and exenatide groups. P-values are for a two-sided Fisher’s exact test, significant events are in bold.